Skip to main content
Equibles
CNSP logo

CNSP · CNS Pharmaceuticals, Inc. · Metrics

Track CNSP — free

Use CNSP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CNSP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.71 -0.28 (-5.61%) At close · Oct 20
Rebalance outlook locked
Market Cap
$7.29M
Shares
1.46M
Volume · Oct 19 5644 Avg daily vol (3M) 6557

CNSP metrics

61 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.99
Market cap
$7.29M

Price action

20 metrics
Price change (1W)
-3.9%
Price change (30D)
-4.4%
Price change (3M)
-9.3%
Price change (6M)
+85.5%
Price change (YTD)
-5.0%
Price change (1Y)
-45.8%
Trailing year
Price change (5Y)
—
52-week high
$9.15
52-week low
$2.13
Change from 52-week high
-45.5%
Change from 52-week low
+134.3%
Annualized volatility
254.4%
Annualized volatility (3M)
74.0%
Beta
0.0
RSI (14D)
42.3
Price vs SMA 50
-8.5%
Price vs SMA 200
+7.8%
Avg volume (3M)
6,557
Relative volume
0.9
Average dollar volume
$36,304

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
1.46M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.4
reciprocal yield 249.6%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-229.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2020-03-12

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$16.92M
Net income (TTM)
−$16.70M
Trailing 12 months
Diluted EPS (TTM)
$-18.08
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-23.36
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-23.17
Operating cash flow per diluted share (TTM)
$-16.27
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$14.52
Stock compensation per diluted share (TTM)
$0.18
Book value per share
$7.15

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1,747.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-91.8%
Return on assets
-76.1%
Debt / equity
—
Current ratio
5.9
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
5.9
Interest coverage
-1,117.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$19.98M
Total assets
$21.94M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$13.41M
Capital expenditures (TTM)
$28,175
R&D (TTM)
$10.11M
SG&A (TTM)
—
Stock compensation (TTM)
$107,916
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
11
13F filer change QoQ
-1
Institutional ownership
19.2%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
17.9%
Private-fund adviser ownership
17.9%
Active holders' share change QoQ
+115.0%
Holder tenure
2.4
Price vs estimated holder cost
-9.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.0%

Short interest

3 metrics
Short interest
0.1%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
30 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1729427 CUSIP 18978H508 Visit website Investor relations